PAREXEL Named to the 2016 Forbes America’s Best Employers List
BOSTON, March 23, 2016— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that Forbes named the Company to the magazine’s America’s “Best Employers” list for 2016. The list features the top 500 U.S. employers with more than 5,000 employees as rated by 30,000 employees in an independent survey.
“We are honored to be named as one of Forbes magazine’s ‘Best Employers’ in the U.S. At PAREXEL, we have a desire to make a difference in the lives of people – and that starts with our own employees,” said Michelle Graham, Corporate Vice President and Chief Human Resources Officer, PAREXEL. “At PAREXEL, our employees are the key to our success. PAREXEL and our clients have a shared mission: to prevent and cure disease by delivering important new medicines and therapies to the patients who need them. PAREXEL accomplishes this important goal through the expertise, experience, innovation and commitment of our employees around the world.”
PAREXEL’s commitment to employees is reflected in the Company’s high performance culture where employees are empowered to speak openly, take ownership, focus on clients, and drive business results, regardless of their role in the organization. The Company also offers employees best-in-class training programs and professional growth opportunities.
About the Forbes America’s Best Employers List Methodology
Now in its second year, the Forbes ranking of America’s Best Employers is drawn from an online survey of more than 30,000 employees at companies with at least 1,000 people. The survey was conducted with global digital data collection partners who use innovative technology and proven sampling methodologies to facilitate a deep understanding of consumer opinions and behavior. Participation in the survey was voluntary, and respondents were recruited from thousands of sources to maximize reach and representation. The mix of respondents (gender, age, region, and ethnicity) in the sample represents American employees. Each employee surveyed was asked to rank both his own employer and other employers in the same industry sector.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 77 locations in 51 countries around the world, and had approximately 18,200 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International Corporation. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #